ERBB2 and neoplasm: In antibody-dependent cell-mediated cytotoxicity assays with BC cell lines and NK cells, the authors showed that the sialidase activity blocked the binding of HER2+ tumour cells to NK cells via SIGLECs, therefore improving the antibody-dependent cellular cytotoxicity (ADCC) response [83].